Population pharmacokinetics of erythropoietin in critically ill subjects

Journal of Clinical Pharmacology

Volumn 45, Issue 2, 2005, Pages 193-202

  Chakraborty, Abhijit ^a   Natarajan, Jaya ^a   Guilfoyle, Mary ^a   Morgan, Nancy ^a   Vercammen, Els ^a   Cheung, Wing ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Critically ill; Erythropoietin (EPO); Pharmacokinetics; Population model

Indexed keywords

ACETYLCYSTEINE; ALPRAZOLAM; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; DIAZEPAM; ERYTHROPOIETIN; FENOTEROL PLUS IPRATROPIUM BROMIDE; FENTANYL; FERROUS GLUCONATE; FUROSEMIDE; IRON; METHYLPREDNISOLONE; MIDAZOLAM; MORPHINE; NADROPARIN; PARACETAMOL; PARAFFIN; POTASSIUM CHLORIDE; PROPACETAMOL; PROPOFOL; RECOMBINANT ERYTHROPOIETIN; SUFENTANIL; VANCOMYCIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONLINEAR SYSTEM; POPULATION MODEL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL;

ALGORITHMS; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; EPOETIN ALFA; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INPATIENTS; INTENSIVE CARE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS;

EID: 16844371796     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269520     Document Type: Article

References (13)

1. Von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care subjects. Crit Care Med. 1999;27:2630-2639.
2. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23:159-162.
3. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000;28:2773-2778.
4. Schobersberger W, Hobisch-Hagen P, Fuchs D, Hoffman G, Jelkmann W. Pathogenesis of anaemia in the critically ill patient. Clin Intensive Care. 1998;9:111-117.
5. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care. 2001;16:36-41.
6. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27:2346-2350.
7. Vincent J-L, Spapen HDMH, Jaspar N, et al. Pharmacokinetics and pharmacodynamics of once-weekly epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med. Submitted for publication.
8. Cheung WK, Goon BL, Guilfoyle MC, Wacholtx MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-423.
9. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001;57:411-418.
10. Naoto H, Haruki K, Eiji Y, Shun H. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. Br J Clin Pharmacol. 1998;46:11-19.
11. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide. San Francisco: NONMEM Project Group, University of California; 1994.
12. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
13. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33:313-327.